Eisai enters strategic API supply deal with Nich-Iko

By Dan Stanton contact

- Last updated on GMT

The active ingredient for Nichi-Iko’s diabetic neuropathy drug will be the first of a number of APIs to be supplied from Eisai’s facility in Vizag, India.

Drug and ingredient maker Eisai has entered into a strategic partnership and ingredient supply deal aimed at expanding and growing fellow Japanese firm Nichi-Iko Pharmaceutical’s generic pharmaceutical business.

The deal will see active pharmaceutical ingredients (APIs) produced from Eisai’s site in Visakhapatnam (Vizag), Andhra Pradesh, India.

Eisai already supplies APIs to Japan for generic makers using the Vizag plant, spokesperson Yasuko Minamida told this publication, and will now begin providing APIs to Nichi-Iko based on this collaboration.

“First item will be epalrestat API, a carboxylic acid derivative which inhibits aldose reductase,” ​we were told.

The ingredient is formulated for drugs to treat diabetic neuropathy, a common long-term complications in patients with diabetes mellitus. “Eisai will supply it to Nichi-Iko in the fourth quarter of fiscal 2018.”

The Vizag site comprises 14 individual buildings across 33 acres, including an API lab, an API building, a drug substance facility, a drug product facility and a QA/QC research lab. Since its completion in 2009, the firm has invested over $20m in expansions and it now boasts annual production capacity to 60t of formulations and two billion tablets.

It is also fulfils Eisai’s ‘high quality price competitive API’ strategy, which according to Minamida fulfils the growing demand for generic API in a tightly-regulated Japanese market.

Maximizing the use of the various functions at the core of the Vizag plant, including research and development, manufacturing, quality management and auditing, we will achieve the supply of high quality price competitive API.”

Total Inclusive Ecosystem

Under terms of the deal, all shares of Eisai subsidiary Elmed Eisai will be transferred to Nichi-Iko and a new business model – called ‘Eisai's Total Inclusive Ecosystem’ – will be set up.

This will allow Eisai to deliver various solutions to address patients’ needs in specific areas with its partners, Minamida said.

“Through the collaboration with Nichi-Iko, who has a wide range of generic pharmaceuticals, we have gained the ability to provide more comprehensive solutions.”

Related news

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Follow us


View more